营收不足40万元、负债率近416%，征祥医药递表港交所

Core Viewpoint - Zhengxiang Pharmaceutical is heavily indebted and is betting its future on a newly approved flu drug, initiating a listing process on the Hong Kong Stock Exchange to alleviate financial pressure and seek funding for development [1] Financial Performance - For the fiscal year 2024 and the first three quarters of 2025, Zhengxiang Pharmaceutical's revenue is projected to be 0 and 355,000 RMB respectively, primarily from drug registration assistance rather than product sales [3] - The company has reported cumulative losses of approximately 1.45 billion RMB for both 2024 and the first three quarters of 2025, with R&D costs of 1 billion RMB and 816.12 million RMB respectively [3] - As of September 2025, the total liabilities of Zhengxiang Pharmaceutical are around 1.26 billion RMB, with a net debt of approximately 956 million RMB and a staggering debt-to-asset ratio of 415.84% [4] Market Competition - The flu antiviral drug market in China is expected to reach 5.7 billion RMB in 2024, with projections to grow to 13.6 billion RMB by 2035, indicating a highly competitive landscape [6] - Zhengxiang Pharmaceutical's core product, Marcilosavir, faces intense competition from established players like Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, which have already entered the insurance reimbursement list [5][6] - Marcilosavir is priced at 222 RMB per box, similar to Roche's product, but competitors offer lower prices, making it less competitive in terms of cost-effectiveness [6][7] Strategic Initiatives - Zhengxiang Pharmaceutical is attempting to differentiate itself by expanding the indications for Marcilosavir and submitting a New Drug Application (NDA) for treating flu in adolescents [7] - The company aims to leverage different formulations and indications to find new growth opportunities, although it faces significant challenges in gaining market share against established competitors [7]